Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301).
Hashimoto K, Morinaga D, Asahina H, Ishidoya M, Kikuchi H, Yokouchi H, Harada T, Honjo O, Shigaki R, Takashina T, Fujita Y, Takahashi M, Kawai Y, Kida R, Ito K, Sukoh N, Takahashi A, Hommura F, Ohhara Y, Furuta M, Konno S, Hosomi Y, Oizumi S; Hokkaido Lung Cancer Clinical Study Group Trial.
Hashimoto K, et al. Among authors: shigaki r.
JTO Clin Res Rep. 2024 Sep 7;5(11):100715. doi: 10.1016/j.jtocrr.2024.100715. eCollection 2024 Nov.
JTO Clin Res Rep. 2024.
PMID: 39403627
Free PMC article.